LakeShore Biopharma Co., Ltd
LSBNASDAQHealthcare
$0.63
+$0.00(+0.00%)
Market Cap$25840359
P/E Ratio—
52W High$8.6
52W Low$0.574
LakeShore Biopharma Co., Ltd (LSB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LSB · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.61B | $0.57B | $0.69B | $0.50B | $0.26B |
| Cost of Revenue | $0.11B | $0.12B | $0.15B | $0.12B | $0.06B |
| Gross Profit | $0.51B | $0.46B | $0.53B | $0.38B | $0.20B |
| Gross Margin %(computed) | 82.47% | 79.48% | 77.68% | 75.85% | 76.79% |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.30B | $0.32B | $0.21B | $0.09B |
| G&A Expenses | $0.14B | $0.15B | $0.08B | $0.11B | $0.14B |
| Total Operating Expenses | $0.59B | $0.90B | $0.67B | $0.50B | $0.32B |
| Operating Income | ($0.09B) | ($0.45B) | ($0.14B) | ($0.12B) | ($0.13B) |
| Operating Margin %(computed) | -14.03% | -77.75% | -20.28% | -23.65% | -48.96% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.04B | $0.03B | $0.00B | $0.03B |
| Income Before Tax | ($0.10B) | ($0.46B) | ($0.28B) | ($0.23B) | ($0.19B) |
| Income Tax Expense | ($0.00B) | ($0.02B) | $0.00B | $0.00B | $0.02B |
| Net Income | ($0.10B) | ($0.43B) | ($0.15B) | ($0.24B) | ($0.19B) |
| Net Margin %(computed) | -16.26% | -75.59% | -21.17% | -47.06% | -74.64% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.94 | $-4.05 | $-1.88 | $-0.02 | $-6.67 |
| Wtd Avg Shares | 0.11B | 0.11B | 0.08B | 0.03B | 0.03B |
| EBITDA | ($0.05B) | ($0.37B) | ($0.08B) | ($0.07B) | ($0.12B) |
| EBITDA Margin %(computed) | -7.89% | -64.29% | -11.18% | -13.36% | -45.44% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CNY · B
Explore more LakeShore Biopharma Co., Ltd data
About LakeShore Biopharma Co., Ltd (LSB) Income Statement
LakeShore Biopharma Co., Ltd (LSB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LSB reported revenue of $0.61B, gross profit of $0.51B (gross margin 82.47%), and net income of ($0.10B) — a net profit margin of -16.26%.
Frequently asked questions
LSB · 4 questionsLakeShore Biopharma Co., Ltd (LSB) reported revenue of $0.61B for 2025, up 7.2% year-over-year.
LSB revenueLSB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09